Radient Pharmaceuticals Corporation focuses on the discovery, development and commercialization of diagnostic tests that help physicians answer clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. The Company is engaged in the development, manufacturing and delivery of products focused in one area, In Vitro Diagnostic Tests for the screening, monitoring and detection of more than 14 different types of cancer. The Company has two subsidiaries: AMDL Diagnostics Inc. and Jade Pharmaceuticals Inc. The Company�s Onko-Sure in vitro diagnostic test enables physicians and their patients to monitor and/or detect solid tumor cancers. The Company�s combination immunogene therapy (CIT) seeks to build the body�s immune system and destroy cancer cells. In December 2010, the Company in partnership with Jaiva Technologies, announced the formation of NuVax Therapeutics, Inc.